A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Trial status: Authorised
Change from baseline to Week 24 in I-RODS., Change from baseline to Week 24 in Mean Grip Strength in the dominant hand., Change from baseline to Week 24 in MRC-SS., Change from baseline to Week 24 in aINCAT score.
The proportion of participants remaining Relapse-free by Week 24.
Description
Change from baseline to Week 24 in I-RODS., Change from baseline to Week 24 in Mean Grip Strength in the dominant hand., Change from baseline to Week 24 in MRC-SS., Change from baseline to Week 24 in aINCAT score.
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 79 participants
Interventions
Placebo is identical to IMP but with no active substance.
БГ